Fortress Biotech, Inc. Noncontrolling Interest, Decrease from Deconsolidation
Fortress Biotech, Inc. (FBIO) reported Noncontrolling Interest, Decrease from Deconsolidation of $9.93 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Shareholders' Equity › Noncontrolling Interest Items
us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation · last filed 2026-08-13
- Fortress Biotech, Inc. noncontrolling interest, decrease from deconsolidation for the quarter ending 2025-12-31 was $0.00.
- Fortress Biotech, Inc. noncontrolling interest, decrease from deconsolidation for the quarter ending 2025-09-30 was $0.00.
- Fortress Biotech, Inc. noncontrolling interest, decrease from deconsolidation for the quarter ending 2025-06-30 was $9.93M.
- Fortress Biotech, Inc. noncontrolling interest, decrease from deconsolidation for the quarter ending 2023-12-31 was $0.00.
- Fortress Biotech, Inc. noncontrolling interest, decrease from deconsolidation for fiscal 2025 was $9.93M.
- Fortress Biotech, Inc. noncontrolling interest, decrease from deconsolidation for fiscal 2023 was $6.69M.
- Fortress Biotech, Inc. noncontrolling interest, decrease from deconsolidation for fiscal 2019 was $4.85M.
| Period end | Noncontrolling Interest, Decrease from Deconsolidation 3 month | Noncontrolling Interest, Decrease from Deconsolidation 6 month | Noncontrolling Interest, Decrease from Deconsolidation 9 month | Noncontrolling Interest, Decrease from Deconsolidation 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $9.93M derived: sum of 3 quarters · filed 2026-08-13 | $9.93M 10-K · filed 2026-03-31 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $9.93M derived: sum of 2 quarters · filed 2026-08-13 | $9.93M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $9.93M 10-Q · filed 2026-08-13 | $9.93M 10-Q · filed 2026-08-13 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $802.00K derived: sum of 2 quarters · filed 2024-03-28 | $6.69M derived: sum of 3 quarters · filed 2024-08-13 | $6.69M 10-K · filed 2024-03-28 |
| 2023-09-30 | $802.00K 10-Q · filed 2023-11-14 | $6.69M derived: sum of 2 quarters · filed 2024-08-13 | $6.69M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $5.89M 10-Q · filed 2024-08-13 | $5.89M 10-Q · filed 2024-08-13 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $4.85M 10-K · filed 2020-03-16 | ||
| 2019-09-30 | $4.85M 10-Q · filed 2019-11-12 | |||
| 2019-03-31 | $4.85M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |